Stamford-Based Sema4 To Begin Layoffs In January

STAMFORD, CT — Sema4, the Stamford-based genomic-testing biotech company, announced earlier this week that it planned on cutting 500 jobs, closing its Stamford laboratory and leaving the reproductive health testing business.

According to a letter from Sema4 Chief People Officer Karen White to the Connecticut Department of Labor, Stamford Mayor Caroline Simmons and Branford First Selectman James Cosgrove, layoffs at three of Sema4's Connecticut offices will begin on Jan. 13, 2023.

The letter was sent on Nov. 15 in accordance with the Worker Adjustment and Retraining Notification Act (WARN).

At Sema4 headquarters located at 333 Ludlow St. in Stamford, there will be 206 affected employees, of which 38 are working remotely within Connecticut, and 111 of whom are working remotely outside the state but report to that office, White said.

The Stamford lab closure will affect 227 employees. White said 31 of them are remote in the state, and 57 are outside of the state. The lab is located at 62 Southfield Ave.

This past August, the company said it planned to leave the somatic tumor testing business, and close the clinical laboratory in Branford, CT, effective Dec. 31, 2022.

Fifteen employees in Branford will be affected, according to the letter from White.

Sema4's announcement this week also came with third quarter financial results for the company.

Total revenue for the third quarter of 2022 was $83.2 million compared to $43.2 million in the third quarter of 2021, according to financials released Monday. Sema4 acquired GeneDx, a genomic testing and analysis firm, earlier this year.

However, the net loss in the third quarter of 2022 was $77.6 million. In the nine months that ended Sept. 30, Sema4 saw a net loss of about $240 million.

Sema4 was spun out of the Icahn School of Medicine at Mount Sinai in June 2017, according to its website.

Read more on Sema4's announcement